Shelley B. Thunen Sells 9,125 Shares of RxSight, Inc. (NASDAQ:RXST) Stock

RxSight, Inc. (NASDAQ:RXSTGet Free Report) CFO Shelley B. Thunen sold 9,125 shares of RxSight stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $47.02, for a total transaction of $429,057.50. Following the completion of the sale, the chief financial officer now owns 13,691 shares of the company’s stock, valued at $643,750.82. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

RxSight Stock Performance

RxSight stock opened at $48.94 on Friday. The company’s fifty day moving average price is $41.86 and its 200 day moving average price is $32.64. RxSight, Inc. has a 1 year low of $12.24 and a 1 year high of $50.20. The stock has a market capitalization of $1.75 billion, a P/E ratio of -28.29 and a beta of 1.21.

RxSight (NASDAQ:RXSTGet Free Report) last released its quarterly earnings results on Thursday, November 9th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.07. RxSight had a negative net margin of 71.87% and a negative return on equity of 39.77%. The firm had revenue of $22.20 million for the quarter, compared to analysts’ expectations of $20.81 million. Sell-side analysts predict that RxSight, Inc. will post -1.53 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have issued reports on RXST. Wells Fargo & Company raised shares of RxSight from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $31.00 to $42.00 in a research report on Wednesday, December 13th. Needham & Company LLC lifted their target price on shares of RxSight from $35.00 to $41.00 and gave the company a “buy” rating in a report on Monday, January 8th. Oppenheimer lifted their target price on shares of RxSight from $50.00 to $54.00 and gave the company an “outperform” rating in a report on Monday, January 29th. Stifel Nicolaus started coverage on shares of RxSight in a report on Tuesday, December 12th. They set a “buy” rating and a $40.00 target price for the company. Finally, Morgan Stanley started coverage on shares of RxSight in a report on Monday, December 4th. They set an “overweight” rating and a $36.00 target price for the company. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $37.63.

View Our Latest Stock Report on RxSight

Institutional Investors Weigh In On RxSight

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Great Lakes Advisors LLC acquired a new position in shares of RxSight during the 4th quarter valued at about $8,226,000. Nicholas Investment Partners LP acquired a new position in shares of RxSight during the 4th quarter valued at about $2,275,000. Counterpoint Mutual Funds LLC acquired a new position in shares of RxSight during the 4th quarter valued at about $270,000. Charles Schwab Investment Management Inc. boosted its position in shares of RxSight by 4.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 190,337 shares of the company’s stock valued at $7,674,000 after acquiring an additional 8,003 shares during the last quarter. Finally, Amalgamated Bank boosted its position in shares of RxSight by 7.7% during the 4th quarter. Amalgamated Bank now owns 4,148 shares of the company’s stock valued at $167,000 after acquiring an additional 298 shares during the last quarter. Institutional investors and hedge funds own 66.51% of the company’s stock.

RxSight Company Profile

(Get Free Report)

RxSight, Inc, an ophthalmic medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.

Featured Articles

Insider Buying and Selling by Quarter for RxSight (NASDAQ:RXST)

Receive News & Ratings for RxSight Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RxSight and related companies with MarketBeat.com's FREE daily email newsletter.